Project Grant R21MH140167
- Federal Grant Award Summary The National Institute of Child Health and Human Development awarded a $3.23 million Project Grant to the University of Michigan for research on "Fragile X Premutations, Mechanisms and Modifiers" under the Child Health and Human Development Extramural Research program (CFDA 93.865). The award, obligated on September 11, 2025, with completion targeted for August 31, 2030, supports a research center structure examining Fragile X-associated conditions (FXACs)—a...
- Federal Grant Award Summary Michigan State University (through its partnership with Henry Ford Health+Michigan State University Health Sciences) received a $431,750 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) to develop transgenic tools and methodologies for accessing semilunar granule cells (SLGCs) in the dentate gyrus of the mouse brain in vivo. The two-year project, awarded March 10, 2026 and concluding March 9,...
- Federal Project Grant Award Summary Emory University received a $430,375 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded July 1, 2025, with completion expected June 30, 2027. This award funds research investigating membrane trafficking impairments in Fragile X Syndrome (FXS), the most common form of inherited intellectual disability and...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded the Regents of the University of Michigan a $3.97 million Project Grant (CFDA 93.242 - Mental Health Research Grants) effective August 1, 2025, through July 31, 2028, to develop a scalable high-plex pipeline for whole-brain proteomics profiling. The project addresses a critical gap in neuroscience research by creating a comprehensive proteomics atlas of the mammalian brain, complementing existing transcriptomics...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded $2.9 million to the Regents of the University of Michigan under the Mental Health Research Grants program (CFDA 93.242) on September 22, 2025, for a four-year project period extending through September 21, 2029. This Project Grant supports basic neuroscience research investigating the neural mechanisms underlying associative learning, with a focus on identifying how midbrain signals contribute to differential...
- Federal Project Grant Award Summary The University of South Carolina received $670,675 in obligated funding from the National Institute of Mental Health (NIMH) Mental Health Research Grants program (CFDA 93.242) beginning September 10, 2025, through August 31, 2030. This P50 Center grant, titled "Translation of the FMR1 Premutation Phenotypes Across the Lifespan," will advance understanding of Fragile X-associated Tremor/Ataxia Syndrome (FXTAS) and Fragile X-associated Neuropsychiatric...
- Federal Project Grant Award Summary Central Michigan University received a $304,250 Project Grant from the National Institute of General Medical Sciences (NIGMS) under the Biomedical Research and Research Training program (CFDA 93.859), effective March 15, 2026, through February 28, 2031. The award funds a five-year research initiative investigating how androgens and social stress regulate oxidative stress in the brain, with the research being conducted in Mount Pleasant, Michigan. The project...
- Federal Grant Award Summary Michigan State University's Henry Ford Health+Michigan State University Health Sciences partnership received a $878,991 Project Grant award from the National Institutes of Health (NIH) Office of the Director under the Trans-NIH Research Support program (CFDA 93.310), effective September 10, 2025, with a completion date of August 31, 2030. The award supports development of genetically encoded Input/Output (I/O) Tags—designer proteins that enable targeted trans-neuronal...
- Federal Grant Award Summary The University of Michigan received a $215,138 Project Grant from the National Institute of Neurological Disorders and Stroke (NINDS) under the Extramural Research Programs in the Neurosciences and Neurological Disorders program (CFDA 93.853), awarded June 10, 2025, with completion targeted for October 31, 2027. The grant supports investigator-initiated research aimed at elucidating the mechanisms by which lipid dysregulation contributes to impaired oligodendrocyte...
- Federal Grant Award Summary The National Institute of Mental Health (NIMH) awarded Icahn School of Medicine at Mount Sinai a Project Grant totaling $844,917 under the Mental Health Research Grants program (CFDA 93.242), effective July 1, 2025, through April 30, 2030. The project, titled "Moderate Effect Size Genes in Autism Spectrum Disorder," delivers research services focused on identifying and characterizing moderate effect size (MES) risk genes that contribute to autism spectrum...
Michigan State University received a $416,859 Project Grant from the National Institute of Mental Health under the Mental Health Research Grants program (CFDA 93.242) awarded on March 3, 2026, with a completion date of February 29, 2028. This exploratory R21 research initiative investigates nucleolar dysfunction as a novel pathological mechanism in Fragile X Syndrome (FXS), a leading genetic cause of intellectual disability and autism spectrum disorders. The research aims to establish whether nucleolar hyper-function contributes to aberrant ribosome biogenesis and the observed global increase in protein synthesis characteristic of FXS pathology. The project delivers three primary research objectives: (1) assessment of neuronal and glial nucleolar function in wild-type and FMR1 knockout mice; (2) comparative genome-wide proteomic analysis of nucleolar proteins to identify molecular alterations in ribosome biogenesis and assembly; and (3) evaluation of nucleolar function in peripheral tissues to establish hyper-functional outcomes as potential clinical biomarkers. Upon completion, this research is expected to reveal previously unexplored cellular mechanisms underlying FXS and identify nucleolus-associated abnormalities as novel molecular and cellular therapeutic targets, potentially advancing understanding of effective medical interventions for this condition.Federal Grant Award Summary
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $416.9k | 3/3/26 |